Vinblastine Interactions

Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-related adverse reactions.

Source: NLP:fosaprepitant dimeglumine

Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits outweigh risks.

Source: NLP:ganciclovir sodium

Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential for higher toxicity from myelosuppression or nephrotoxicity.

Source: NLP:valganciclovir hydrochloride

Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-related adverse reactions.

Source: NLP:aprepitant

Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-related adverse effects.

Source: NLP:fosaprepitant

Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.

Source: NLP:ganciclovir

Netupitant inhibits CYP3A4, increasing plasma concentrations of concomitant CYP3A4 substrates for 6 days; avoid concomitant use for one week if feasible, or consider dose reduction.

Source: NLP:netupitant and palonosetron

CYP3A4 inhibitor that may increase tolterodine plasma concentrations. Dose reduction to 1 mg twice daily is recommended.

Source: NLP:tolterodine tartrate

Drug associated with myelosuppression or nephrotoxicity. Consider coadministration only if potential benefits outweigh risks.

Source: NLP:valganciclovir